assertion
Analysis v1
16
Pro
0
Against

MOTS-c, a mitochondrial peptide, reduces visceral and liver fat and improves insulin sensitivity even on a poor diet by activating AMPK, the cell’s energy sensor, which improves glucose uptake and fuel efficiency.

Scientific Claim

MOTS-c reduces visceral and hepatic fat and improves insulin sensitivity even on a high-fat diet by activating AMPK, the cellular energy sensor, which enhances glucose uptake, insulin signaling, and fuel efficiency.

Original Statement

So tesamellin works upstream through growth hormone and IGF signaling and then MOS works inside the cell in the trenches directly at the level of the mitochondrial metabolism. So there's a study in cell metabolism that showed that MOS C reduced visceral fat, reduced liver fat, and improved insulin sensitivity even on a poor diet. But the mechanism was different. Instead of stimulating growth hormone pathways, MOT C activated AMPK, which is the cell's energy sensor. So improving glucose uptake, insulin signaling, and fuel efficiency.

Context Details

Domain

pharmacology

Population

animal

Subject

MOTS-c

Action

reduces

Target

visceral and hepatic fat and improves insulin sensitivity by activating AMPK

Intervention Details

Type: drug
Dosage: 0.5–5 mg/kg/day
Duration: 7–8 weeks

Evidence from Studies

Supporting (3)

16

This study found that MOTS-c helps prevent muscle loss and improves lipid metabolism in mice, which supports the idea that MOTS-c can improve insulin sensitivity.

This study found that a tiny molecule from mitochondria, called MOTS-c, helps mice stay healthy even when eating lots of fat by turning on a cellular energy switch (AMPK) that improves how the body uses sugar and stores less fat.

This study found that targeting certain immune cells in the gut can improve blood sugar control in obese mice, which supports the idea that MOTS-c can improve insulin sensitivity by affecting similar pathways.

Contradicting (0)

0
No contradicting evidence found